Six‐year experience with treatment of early donor‐specific anti‐HLA antibodies in pediatric lung transplantation using a human immunoglobulin‐based protocol
Authors:
Open Access
- 7 January 2020
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 55 (3) , 754-764
Abstract
Objectives: Experience with the treatment of early donor‐specific anti‐HLA antibodies (eDSA) after lung transplantation in children is very limited. At our institution, we have treated patients with eDSA since 2013 with successive infusions of intravenous human immunoglobulins (IVIG), combined in some cases with a single dose of Rituximab and plasmapheresis (therapeutic plasma exchange [tPE]) or immunoabsorption. The aim of this study was to present the 6‐year results of IVIG‐based therapy in pediatric lung recipients.Methods: Records of pediatric (P = .65); freedom (%) from chronic lung allograft rejection (CLAD) was 89 vs 78 (P = .82); and from infection 47 vs 31 (P = .15), in IVIG vs control patients, respectively.Conclusions: After lung transplantation, an IVIG‐based treatment for eDSA yielded high eDSA clearance. IVIG and control patients showed similar CLAD‐free and graft survival.Keywords
This publication has 32 references indexed in Scilit:
- De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantationThe Journal of Heart and Lung Transplantation, 2014
- De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantationThe Journal of Heart and Lung Transplantation, 2014
- Early donor-specific antibodies in lung transplantation: Risk factors and impact on survivalThe Journal of Heart and Lung Transplantation, 2014
- Pre-transplant donor HLA-specific antibodies: Characteristics causing detrimental effects on survival after lung transplantationThe Journal of Heart and Lung Transplantation, 2014
- Acute antibody-mediated rejection after lung transplantationThe Journal of Heart and Lung Transplantation, 2013
- Measurement of donor‐specific HLA antibodies following plasma exchange therapy predicts clinical outcome in pediatric heart and lung transplant recipients with antibody‐mediated rejectionJournal of Clinical Apheresis, 2013
- Clinical Aspects of Intravenous Immunoglobulin Use in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2011
- Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantationThe Journal of Heart and Lung Transplantation, 2010
- Mechanisms of Foxp3+ T Regulatory Cell-Mediated SuppressionImmunity, 2009
- Immunoglobulin M‐enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal activity of human serumXenotransplantation, 2004